Edgewise Therapeutics, Inc. (EWTX) Q1 2021 Earnings Results

Edgewise Therapeutics Beats on EPS, Stock Down 4.29%

Edgewise Therapeutics reported a narrower loss than expected, which is a positive sign for investors. However, the stock fell by 4.29% in reaction, likely due to the lack of revenue information and guidance. Investors may be concerned about the company's future prospects without clear direction.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	-$0.14	N/A	+10.83%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management expressed a cautious optimism about their pipeline and future developments. They noted the significance of upcoming milestones.

Management highlighted ongoing progress in their clinical trials.

They emphasized the importance of upcoming data releases for future growth.

Edgewise Therapeutics Beats on EPS, Stock Down 4.29%

Key numbers

Management commentary

Edgewise Therapeutics, Inc.

More earnings this week

Edgewise Therapeutics Beats on EPS, Stock Down 4.29%

Key numbers

Management commentary